AstraZeneca's Brilinta Didn't Meet Primary Endpoint

AstraZeneca plc AZN disclosed top-line results from the EUCLID study revealing that Brilinta failed to demonstrate a gain over clopidogrel in a symptomatic peripheral artery disease (PAD) patient population. This meant that the study failed to meet the primary endpoint.

The company enrolled 13,885 patients from 28 nations for EUCLID study, which is the biggest cardiovascular study conducted in patients with PAD. The study assessed the treatment of Brilinta 90 mg tablets twice a day compared to clopidogrel 75 mg once a day for atherothrombotic events prevention.

AstraZeneca indicated its preliminary analyses suggested that safety data was consistent with the stated safety profile of Brilinta.

Related Link: The Drug Price Increase Debate: Separating The Winners From The Losers

The company's EVP for Global Medicines Development and Chief Medical Officer, Sean Bohen, commented, "The proven benefits of Brilinta in acute coronary syndrome and post-myocardial infarction patients are established and remain unchanged. We are disappointed that the EUCLID trial results showed Brilinta did not demonstrate a benefit over clopidogrel in this specific symptomatic PAD population."

The drugmaker expects the complete results to be presented at the American Heart Association Scientific Sessions in New Orleans in November.

Following the news, the stock shed $0.25, or 0.76 percent, to $32.75.